Tumor necrosis factor antagonist mechanisms of action: A comprehensive review, Pharmacology & Therapeutics, vol.117, issue.2, pp.244-79, 2008. ,
DOI : 10.1016/j.pharmthera.2007.10.001
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19 ,
DOI : 10.1001/jama.295.19.2275
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.62, issue.90002 ,
DOI : 10.1136/ard.62.suppl_2.ii30
Potential Complications Associated with the Use of Biologic Agents for Psoriasis, Dermatologic Clinics, vol.25, issue.2, pp.207-220, 2007. ,
DOI : 10.1016/j.det.2007.01.010
Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases, Journal of Dermatological Treatment, vol.174, issue.15, pp.100-108, 2009. ,
DOI : 10.1016/S0140-6736(02)08512-4
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease, Journal of Crohn's and Colitis, vol.7, issue.10, pp.769-79, 2013. ,
DOI : 10.1016/j.crohns.2013.01.009
Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action, Arthritis & Rheumatism, vol.44, issue.7, pp.996-1001, 2008. ,
DOI : 10.1002/art.23835
Review article: anti TNF-?? induced psoriasis in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.27, issue.9, pp.921-928, 2009. ,
DOI : 10.1111/j.1365-2036.2009.03955.x
Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature, Aliment Pharmacol Ther. déc, vol.34, pp.11-121318, 2011. ,
Assessing inter-rater reliability for rating scales: resolving some basic issues The measurement of observer agreement for categorical data, Br J Psychiatry J Ment Sci. nov, vol.129, issue.11, 1976. ,
Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy, 159?74. 12. Devos SA, pp.388-90, 1977. ,
Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not?, Arch Dermatol. déc, vol.143, issue.12, pp.1593-1598, 2007. ,
Psoriasiform Drug Eruptions Under Anti-TNF Treatment of Arthritis are Not True Psoriasis, 77?80. 15. Tillack C, Ehmann LM, 2007. ,
DOI : 10.2340/00015555-0193
induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-?-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment Infliximabinduced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms, 567?77. 16. Sherlock ME, pp.512-520, 2013. ,
Cytokine imbalance with increased production of interferon-?? in psoriasiform eruptions associated with antitumour necrosis factor-?? treatments, British Journal of Dermatology, vol.202, issue.5, pp.1081-1089, 2009. ,
DOI : 10.1111/j.1365-2133.2009.09329.x
Psoriasis induced by infliximab in a patient suffering from Crohn's disease Tumor necrosis factor biology in experimental and clinical arthritis Cross-regulation of TNF and IFN-alpha in autoimmune diseases Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions, 3372?7. 21. de Gannes GC, pp.223-254, 2003. ,
Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors Efalizumab-induced guttate psoriasis. Successful management and re-treatment Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects, 182?4. 24. Firmin D, pp.203-209, 2005. ,
Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma, Journal of Experimental Medicine, vol.146, issue.3, pp.720-754, 1977. ,
DOI : 10.1084/jem.146.3.720
An endotoxin-induced serum factor that causes necrosis of tumors., Proceedings of the National Academy of Sciences, vol.72, issue.9, pp.3666-70, 1975. ,
DOI : 10.1073/pnas.72.9.3666
Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française -Anti-TNF_V_Goeb.pdf [Internet]. [cité 23 sept 2015] Disponible sur: http://sfr.larhumatologie.fr/rc/rhumatologie Disponible sur: https://www.getaid.org/images/outils/adalimumab_maj_2011_dp, Disponible sur, 2013. ,
with refractory IBD--pro: anti-TNF or immunosuppressive treatment 1:116?21. 13. Sousa P, Allez M. Complications of biologics in inflammatory bowel disease Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti- TNF alpha antibodies, 296?302. 14. Beigel F, pp.735-779, 2014. ,
DOI : 10.1159/000367861
Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease Psoriasiform eruption induced by infliximab Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction, 769?79. 16. Verea MM, pp.223-254, 2004. ,
Psoriasiform Drug Eruptions Under Anti-TNF Treatment of Arthritis are Not True Psoriasis, Acta Dermato-Venereologica, vol.87, issue.1, pp.77-80, 2007. ,
DOI : 10.2340/00015555-0193
Cytokine imbalance with increased production of interferon-?? in psoriasiform eruptions associated with antitumour necrosis factor-?? treatments, British Journal of Dermatology, vol.202, issue.5, pp.1081-1089, 2009. ,
DOI : 10.1111/j.1365-2133.2009.09329.x
Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?):438?9. 22. English PL, Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab, J Rheumatol. févr J Cutan Med Surg. févr, vol.3413, issue.21, pp.40-42, 2007. ,
Psoriasis induced by infliximab in a patient suffering from Crohn's disease Cross-regulation of TNF and IFN-alpha in autoimmune diseases, Int J Immunopathol Pharmacol. sept Proc Natl Acad Sci U S A. 1 mars, vol.22102, issue.249, pp.3372-3379, 2005. ,
Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors Role of NFkappaB in the apoptotic-resistant phenotype of keratinocytes, Rheumatol Oxf Engl. févr J Biol Chem. 31 déc, vol.44274, issue.253, pp.172-177, 1999. ,
Induction and exacerbation of psoriasis with TNFblockade therapy: a review and analysis of 127 cases100?8. 29. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD Efalizumab-induced guttate psoriasis. Successful management and re-treatment Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects, 203?6. 32. Tillack C, Ehmann LM, 2008. ,
Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment Infliximabinduced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease, 512?8. 34. Fiorino G, pp.921-928, 2009. ,
Crohn's disease: a prospective cohort study C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity, 32?9. 361353?64. 37. Casiano CA, Tan EM. Recent developments in the understanding of antinuclear autoantibodies308?13. 38. Hanauer SB, 1996. ,
Histological features of palatine tonsils in pustulosis palmaris et plantaris: A morphometric study, Pathology International, vol.401, issue.Suppl., pp.186-93, 1994. ,
DOI : 10.1111/j.1440-1827.1994.tb02591.x
Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: relation to focal infection and response to treatments Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action, 8?15. 41. Collamer AN, pp.996-1001, 1995. ,
Vasculitis associated with tumor necrosis factor-? inhibitors Autoimmune diseases induced by biological agents: a double-edged sword?, ):739?45. 43. Ramos-Casals M188?93. 44. Wiik A. Drug-induced vasculitis, pp.35-44, 2008. ,
Drug-Induced Lupus due to Anti-Tumor Necrosis Factor ?? Agents, Seminars in Arthritis and Rheumatism, vol.37, issue.6, pp.381-388, 2008. ,
DOI : 10.1016/j.semarthrit.2007.08.003
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey, Arthritis Research & Therapy, vol.7, issue.3, pp.545-51, 2005. ,
DOI : 10.1186/ar1715
Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections, Annals of the Rheumatic Diseases, vol.61, issue.4, pp.358-61, 2002. ,
DOI : 10.1136/ard.61.4.358
Lichen planus under anti TNF therapy for ankylosing spondylitis Letter: Lichenoid eruption induced by etanercept, Jt Bone Spine Rev Rhum. mars Dermatol Online J. juill, vol.8018, issue.27, pp.227-235, 2012. ,
Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapyParadoxical cutaneous manifestations during anti-TNF-alpha therapy], 883?6. 51. Devos SA388?90. 52. Viguier M, pp.64-71, 2003. ,
Lupus attributable to anti-TNF therapy and revealed by interstitial granulomatous dermatitis, Rheumatology International, vol.126, issue.1 ,
DOI : 10.1007/s00296-011-2016-6
Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-?? blocker agents, Journal of the European Academy of Dermatology and Venereology, vol.53, issue.4, pp.479-84, 2011. ,
DOI : 10.1111/j.1468-3083.2010.03770.x
Pelade au cours d???un traitement par anti-TNF alpha??: neuf cas, Annales de Dermatologie et de V??n??r??ologie, vol.138, issue.4, pp.285-93, 2011. ,
DOI : 10.1016/j.annder.2011.01.047
Induction or exacerbation of psoriatic lesions during anti-TNF-? therapy for inflammatory bowel disease: a systematic literature review based on 222 cases Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature, 517?24. 58, pp.11-121318, 2011. ,
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor ?? therapy: results from the British Society for Rheumatology Biologics Register, Annals of the Rheumatic Diseases, vol.68, issue.2, pp.209-224, 2009. ,
DOI : 10.1136/ard.2007.087288